Filing Details

Accession Number:
0001209191-16-142260
Form Type:
4
Zero Holdings:
No
Publication Time:
2016-09-21 16:08:42
Reporting Period:
2016-09-20
Filing Date:
2016-09-21
Accepted Time:
2016-09-21 16:08:42
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
907654 Arca Biopharma Inc. ABIO In Vitro & In Vivo Diagnostic Substances (2835) 363855489
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1290482 A Thomas Keuer 11080 Circlepoint Road
Suite 140
Westminster CO 80020
Chief Operating Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2016-09-20 714 $2.89 15,383 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
Footnotes
  1. Represents shares of common stock sold pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person with respect to the vesting of previously reported Restricted Stock Units ("RSUs") granted to the Reporting Person under the Issuer's 2013 Amended and Restated Equity Incentive Plan (the "Plan")
  2. The price represents the weighted average sale price for multiple transactions reported on this line. The prices of the transactions ranged from $2.88 to $2.89. Upon request of the SEC staff, ARCA biopharma, Inc. (the "Company") or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold at each separate price.
  3. Includes (i) remaining 1,429 previously reported shares issued as RSUs under the Plan that vests on 10/15/16, (ii) remaining 2,443 previously reported shares issued as RSUs under the Plan that vest in two equal annual installments beginning on 2/27/17, and (iii) 2,414 previously reported shares issued as RSUs under the Plan that vest in two equal annual installments beginning 4/2/17, provided that the Reporting Person's continuous service to the Issuer has not been terminated as defined under the Plan; and 9,097 previously reported shares of common stock owned.